跳至主要内容
临床试验/NL-OMON54411
NL-OMON54411已完成不适用

Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - A Prospective Multicenter Study. - AAA-SHAPE_NLD

Shape Memory Medical0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1. >=18 years of age.
  • 2. A candidate for elective EVAR of an infrarenal aortic aneurysm >=5.5 cm in
  • diameter in men and >=5.0 cm in women.

排除标准

  • 1. An inability to provide informed consent.
  • 2. Enrolled in another clinical study.
  • 3. Aortoiliac aneurysm, or concomitant iliac artery ectasia or aneurysm (common
  • iliac artery diameter >24 mm) close to the bifurcation and/or that cannot be
  • adequately sealed.
  • 4. Patent AAA sac feeding vessels (within the sac) >4 mm in diameter.
  • 5. Volume of AAA sac to be filled after stent graft placement <20 mL or >135
  • mL, based on pre-procedure CTA (i.e., aortic flow volume exclusive of stent
  • graft volume).
  • 6. Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis,
  • Cook Zenith Flex AAA Endovascular Graft, or Medtronic Endurant II Stent Graft
  • to treat the AAA.
  • 7. Planned use of the chosen stent graft outside its instructions for use (IFU).
  • 8. Planned use of fenestrated or chimney stent grafts.
  • 9. Study participants in which stent graft placement is abandoned for any
  • reason, and/or in which the investigator decides, during the course of the
  • stent graft placement, that the study procedure may not be appropriate.
  • 10. Planned use of embolic devices other than the investigational product to
  • embolize the AAA sac.
  • 11. Vascular disease and/or anatomy that preclude the safe access and
  • positioning of a catheter to deliver the investigational product into the AAA
  • 12. Ruptured, leaking, or mycotic (infected) aneurysm.
  • 13. Aneurysmal disease of the descending thoracic aorta.
  • 14. Coagulopathy or uncontrolled bleeding disorder.
  • 15. Long-term (>6 months prior to the procedure) use of direct oral
  • anticoagulant or any vitamin K antagonist anticoagulant use.
  • 16. Serum creatinine level >2.5 mg/dL.
  • 17. Cerebrovascular accident within 3 months prior to the procedure.
  • 18. Myocardial infarction and/or major heart surgery within 3 months prior to
  • the procedure.
  • 19. Atrial fibrillation that is not well rate controlled.
  • 20. Unable or unwilling to comply with study follow-up requirements.
  • 21. Life expectancy of <2 years post-procedure.
  • 22. Known hypersensitivity or contraindication to platinum, iridium, or
  • polyurethane.
  • 23. A condition that inhibits radiographic visualization during the
  • implantation procedure.
  • 24. History of allergy to contrast medium that cannot be managed medically.
  • 25. Uncontrolled co-morbid medical condition, including mental health issues,
  • that would adversely affect participation in the study.
  • 26. Pregnant or a lactating female. For females of child-bearing potential,
  • based on a positive pregnancy test within 7 days prior to the procedure or
  • refusal to use a medically accepted method of birth control for the duration of
  • 27. Member of a vulnerable population.

研究者

发起方
Shape Memory Medical

相似试验

Abdominal Aortic Aneurysm Sac Healing and Prevention... | 临床试验